Andre Goy, MD, John Theurer Cancer Center

How CTCs and Circulating Naked Tumor DNA-as Liquid Biopsies-Will Transform Diagnostic and Management of Oncology Patients

The changes seen in multiple myeloma are a perfect illustration of a potentially shifting paradigm in cancer care.

Numerous epidemiological factors affect the likelihood of developing breast and ovarian cancer, but no other predictor is as powerful as an inherited mutation in BRCA1 or BRCA2, genes involved in both tumor suppression and DNA repair.

A disruptive study challenges our current system in classifying cancer. Will a new molecular taxonomy of tumors arise and change our views on patient management?

The ASCO annual meeting is always a time of excitement for the nearly 30,000 clinicians and scientists who gather every year to see "what's new."

The measurement of response to anticancer therapy has evolved over the years as a result of better therapies and progress in imaging.

The National Comprehensive Cancer Network (NCCN) guidelines have been a very valuable resource for practicing oncologists for 15 years.

Andre Goy, MD, MS, chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses NCCN guidelines for the treatment of lymphomas.

Medicine is undergoing a revolution that will transform the practice of healthcare, including oncology.

Andre Goy, MD, MS, chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses emerging agents in lymphoma.

There is no question that the era of precision medicine has arrived, and we need to embrace it and resolve together the challenges that come with it, including at the regulatory level.

Andre Goy, MD, MS, chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses the challenges of treating patients with Hodgkin's lymphoma.

Andre Goy, MD, MS, from the John Theurer Cancer Center, discusses the apparent effectiveness of CD19-targeted CAR-modified T cells as a treatment for patients with various types of lymphoma.

Andre Goy, MD, Chairman and Director and Chief of Lymphoma at John Theurer Cancer Center, comments on the recent developments in fighting cancer with the immune system.

Andre Goy, MD, Chairman and Director and Chief of Lymphoma at John Theurer Cancer Center, discusses the approval of the immunomodulatory agent lenalidomide (Revlimid).

Dr. Andre Goy, from John Theurer Cancer Center, Highlights Research From the 2012 ASCO Meeting.

Dr. Andrew Goy, from John Theurer Cancer Center, on Neoadjuvant Hormonal Therapy Plus Zytiga

Dr. Andre Goy, from John Theurer Cancer Center, on Crizotinib for Pediatric Patients With ALCL

Dr. Andre Goy from John Theurer Cancer Center Explains the Concept of Personalized Medicine

Dr. Andre Goy from John Theurer Cancer Center Highlights Recent Advances in Oncology

Dr. Andre Goy from John Theurer Cancer Center on Integrating Novel Therapies Into the JTCC Conference

Dr. Andre Goy from John Theurer Cancer Center on the Upcoming Conference at John Theurer Cancer Center